First published

Long Term: Veeva Systems: regulated CRM switching costs

Explore this signal

Long Term at a glance

Short reader summary

If drug makers adopt Vault CRM and Veeva agents together, regulated workflows could lift recurring subscriptions before the separate AI contribution becomes visible in reported cash.

Exact asset or item

Veeva Systems

Asset type

Listed investment

Reference price

301.53

Currency code

USD

Price observed at

2026-11-13T16:00:00-05:00

What this number represents

Tracking price

What remains unproven

Historical tracking close, not a purchase or current executable quote. AI revenue contribution and future returns are not established.

Exact asset or item

Exact asset or item

Veeva Systems

Asset type

Listed investment

Ticker

VEEV

Exchange

NYSE

How to identify this exact asset

Category: Shares Exact asset: NYSE: VEEV Country and currency: United States / USD Published: 15 November 2026, 15:58 SGT Information cutoff: 15 November 2026, 15:58 SGT Main time horizon: 2 years Current position: RESEARCH WATCH: revenue durability established, incremental AI revenue not isolated

Price and what it means

Entry or reference price

301.53

Currency code

USD

Price observed at

2026-11-13T16:00:00-05:00

What this number represents

Tracking price

Price evidence status

Verified

Price source

8. VEEV dated trading history | Stock Analysis | Original: 13 Nov 2026 quote | US / English.

Publisher: Stock Analysis

Reading access: partial

published date precision: day

retrieved date precision: day

Source publication date 2026-11-13

Source retrieval date 2026-11-16

Matching price source ID

VEEV-S8

Purchase, sale and realised profit

Original entry price and date (permanent, frozen field): US$301.53 per share, 13 Nov 2026 16:00 EST, US market closing reference; original source: https://stockanalysis.com/stocks/veev/history/. Latest checked price: same closing price only; no later independent regular-session quote available as of report cutoff. Price change: 0.00% since frozen tracking snapshot only, not an actual investment return. Estimated result after costs: NOT ASSESSABLE; unknown broker spread, commission, custody, FX, distributions and taxes; no costs were incurred by this research. Actually sold? NO, no purchase executed. Forecast status: NOT YET DUE; these are first-publication scenarios. Next review: 2026-12-03. Do not rewrite the frozen original price or forecast when new evidence appears; append a separately dated update.

The developments we connected

Separate development

  1. What changed

    125+ live customers

    Date of the development

    Evidence status

    Observed

    What the evidence shows

    125+ live customers

    Source IDs

    • VEEV-S3
  2. What changed

    Fiscal Q2 reported revenue

    Date of the development

    Evidence status

    Observed

    What the evidence shows

    Fiscal Q2 reported revenue

    Source IDs

    • VEEV-S1
  3. What changed

    190 live customers and new selection

    Date of the development

    Evidence status

    Observed

    What the evidence shows

    190 live customers and new selection

    Source IDs

    • VEEV-S4

Emerging insight

REPORT A (3 March): more than 125 regulated firms have migrated to a working CRM. -> REPORT B (26 August): subscription revenue is already growing at the issuer level. -> REPORT C (23 September): new commitments may deepen the installed base. HIDDEN TEST: if additional agent features attach to migrations without a proportional rise in implementation cost, Veeva could earn more subscription income per customer. The public reports do not prove that separate agent subscriptions already generate material revenue.

How this exact asset could benefit

Beneficiary: Veeva Systems, selling subscription software for biopharma commercial and development workflows. Proven: company-level subscription sales and reported Vault CRM live deployments. Not proven: the incremental annual recurring revenue, margin or cash from agents specifically, plus how quickly newly selected clients go live. A repeatable multi-year subscription could support future earnings if customers renew; price appreciation is not guaranteed.

Who could benefit

  1. Who

    Veeva Systems

    How they could benefit

    Beneficiary: Veeva Systems, selling subscription software for biopharma commercial and development workflows. Proven: company-level subscription sales and reported Vault CRM live deployments. Not proven: the incremental annual recurring revenue, margin or cash from agents specifically, plus how quickly newly selected clients go live. A repeatable multi-year subscription could support future earnings if customers renew; price appreciation is not guaranteed.

    Evidence status

    Still unproven

What we observed

3 March 2026: Veeva said more than 125 customers were live on Vault CRM. 3 June: it reported fiscal-2027 Q1 revenue of approximately US$882.9m. 26 August: fiscal Q2 revenue rose to approximately US$928m, including US$766.8m subscription revenue. 23 September: Veeva said approximately 190 customers were live and that a further large biopharma customer selected Vault CRM. Live customers, announced selections and revenue are different measures; an announced selection can still take time to deploy.

What remains unproven

Beneficiary: Veeva Systems, selling subscription software for biopharma commercial and development workflows. Proven: company-level subscription sales and reported Vault CRM live deployments. Not proven: the incremental annual recurring revenue, margin or cash from agents specifically, plus how quickly newly selected clients go live. A repeatable multi-year subscription could support future earnings if customers renew; price appreciation is not guaranteed.

What to check before acting

Entry conditions

The US$301.53 reference is an ordinary unadjusted closing market snapshot, not proof of a cheap entry. Study the valuation against GAAP earnings, free-cash-flow margin, share-based compensation and retained subscriptions. Some stock portals show high multiples, which makes even good operations risky if growth slows. No separately reliable AI-attach model was available, so a justified entry discount or numerical fair value is NOT estimated.

Possible upside

Customers adopt paid agent functions at attractive margins and operating cash follows.

Possible downside

Implementation delays, competition or valuation compression could materially reduce the quoted share price.

Price or return range method

Downside: implementation delays, competition or valuation compression could materially reduce the quoted share price. Base case: existing software subscription growth persists, while AI attachment stays small or undisclosed. Upside: customers adopt paid agent functions at attractive margins and operating cash follows. Numerical downside/base/upside price ranges: NOT ESTIMATED, because attach rates, long-term margins and discount-rate assumptions cannot be defended from current disclosures. These are conditional qualitative paths, not guaranteed share prices, profits or investment advice.

Costs and fees

Trading spread, commission, custody and SGD-USD exchange fees vary by broker; applicable investor tax treatment not assessed.

How hard it may be to sell

Exchange-listed shares normally trade during market hours, subject to price gaps, volatility and broker access.

Key risks

Main risk: a strong product story has been fully priced in. Alternative: customer migrations are replacements rather than expansion. Exact disproof: over two successive fiscal reports, subscription growth weakens materially while CRM live deployments/agent products rise but operating cash and renewal measures do not improve. Liquidity: exchange-listed shares normally trade during market hours, subject to price gaps, volatility and broker access. Trading spread, commission, custody and SGD-USD exchange fees vary by broker; applicable investor tax treatment not assessed.

What an ordinary reader can do next

Read Veeva latest earnings and SEC filing, then track the distinction among selected, deployed, renewed, invoiced and collected contracts. Request an actual broker quote and check spreads/fees before any action. Reassess if the next two reports do not quantify the cash consequence of migration and agents. This is not suitable for every reader. Issuer investor calendar listed fiscal-2027 third-quarter results for 3 December 2026; verify that event date again before relying on it. Test actual subscription growth, cash from operations, software margins and commentary about AI products. An announced customer is not a new earned subscription until recognised under accounting rules.

Original forecast record

Original forecast in full

Long Term: Veeva Systems: regulated CRM switching costs

Category: Shares

Exact asset: NYSE: VEEV

Country and currency: United States / USD

Published: 15 November 2026, 15:58 SGT

Information cutoff: 15 November 2026, 15:58 SGT

Main time horizon: 2 years

Current position: RESEARCH WATCH: revenue durability established, incremental AI revenue not isolated

Publication clarification, 16 November 2026 (SGT): The source's Published timestamp above is the dossier issue time, not this website article's first-publication time.

The opportunity in one sentence

If drug makers adopt Vault CRM and Veeva agents together, regulated workflows could lift recurring subscriptions before the separate AI contribution becomes visible in reported cash.

Entry price and date

Reference entry price: US$301.53 per share; observed 13 Nov 2026 at 16:00 EST (14 Nov 2026 at 05:00 SGT). Market: US equity closing snapshot via Stock Analysis; quote type: historical market quote, not an offer or completed purchase. Ordinary-reader availability: the listed share may be available from an authorised broker where supported; check local access, liquidity, prices and fees. Entry note: TRACKING PRICE ONLY. NO ACTUAL PURCHASE. On Sunday 15 November, the US market is closed. The quote source and exact class are frozen in the tracking record below.

What changed?

3 March 2026: Veeva said more than 125 customers were live on Vault CRM. 3 June: it reported fiscal-2027 Q1 revenue of approximately US$882.9m. 26 August: fiscal Q2 revenue rose to approximately US$928m, including US$766.8m subscription revenue. 23 September: Veeva said approximately 190 customers were live and that a further large biopharma customer selected Vault CRM. Live customers, announced selections and revenue are different measures; an announced selection can still take time to deploy.

Reported quarterly revenue, not agent-specific cashUS$ million
Horizontal scale 0 to 1000Ticks 0 · 250 · 500 · 750 · 1000
View chart values
Reported quarterly revenue, not agent-specific cash
QuarterRevenue
FY2027 Q1882.9
FY2027 Q2928
Company-wide reported revenue. Q2 subscription revenue of US$766.8 million is included, not additional. Neither series isolates agent revenue or cash receipts.

The connection most people may miss

REPORT A (3 March): more than 125 regulated firms have migrated to a working CRM. -> REPORT B (26 August): subscription revenue is already growing at the issuer level. -> REPORT C (23 September): new commitments may deepen the installed base. HIDDEN TEST: if additional agent features attach to migrations without a proportional rise in implementation cost, Veeva could earn more subscription income per customer. The public reports do not prove that separate agent subscriptions already generate material revenue.

Conditional path from selection to collected cash
  1. SelectedAnnounced customer commitment
  2. DeployedWorking Vault CRM installation
  3. Renewed and invoicedRetention and paid contract terms need evidence
  4. CollectedCash receipt and margins need evidence
Conceptual evidence sequence, not proof that every customer completes every stage. Cancellation rights and implementation cost can weaken conversion.

How this could make money

Beneficiary: Veeva Systems, selling subscription software for biopharma commercial and development workflows. Proven: company-level subscription sales and reported Vault CRM live deployments. Not proven: the incremental annual recurring revenue, margin or cash from agents specifically, plus how quickly newly selected clients go live. A repeatable multi-year subscription could support future earnings if customers renew; price appreciation is not guaranteed.

Why the entry price matters

The US$301.53 reference is an ordinary unadjusted closing market snapshot, not proof of a cheap entry. Study the valuation against GAAP earnings, free-cash-flow margin, share-based compensation and retained subscriptions. Some stock portals show high multiples, which makes even good operations risky if growth slows. No separately reliable AI-attach model was available, so a justified entry discount or numerical fair value is NOT estimated.

Time-horizon forecast

Time-horizon forecast
Time-horizon forecast
HorizonReview dateWhat we expect or need to seeWhat would challenge it
6 months2027-05-15Count deployed Vault CRM customers in next issuer updateCustomer churn or implementation overruns already evident
1 year2027-11-15Compare new subscriptions and agent product pricing with cash generationSubscription growth slows while expenses accelerate
2 years2028-11-15Look for a separately disclosed AI/CRM renewal cohortManagement still does not isolate monetisation
3 years2029-11-15Look for operating cash growth exceeding equity dilution over two fiscal cyclesCash growth stalls despite rising reported adjusted metrics
4 years2030-11-15Test sustained customer retention and returns on product investmentMajor customers migrate to alternative software
5 years2031-11-15Check five-year subscription mix versus competitive pricing pressureLegacy platform disruption or falling renewal rates
Exact original six-horizon conditions; no guaranteed price or investment return.
Sources
  • Original Veeva dossier, 15 November 2026 15:58 SGT

Possible price outcomes

Downside: implementation delays, competition or valuation compression could materially reduce the quoted share price. Base case: existing software subscription growth persists, while AI attachment stays small or undisclosed. Upside: customers adopt paid agent functions at attractive margins and operating cash follows. Numerical downside/base/upside price ranges: NOT ESTIMATED, because attach rates, long-term margins and discount-rate assumptions cannot be defended from current disclosures. These are conditional qualitative paths, not guaranteed share prices, profits or investment advice.

What could go wrong?

Main risk: a strong product story has been fully priced in. Alternative: customer migrations are replacements rather than expansion. Exact disproof: over two successive fiscal reports, subscription growth weakens materially while CRM live deployments/agent products rise but operating cash and renewal measures do not improve. Liquidity: exchange-listed shares normally trade during market hours, subject to price gaps, volatility and broker access. Trading spread, commission, custody and SGD-USD exchange fees vary by broker; applicable investor tax treatment not assessed.

What an ordinary person can do

Read Veeva latest earnings and SEC filing, then track the distinction among selected, deployed, renewed, invoiced and collected contracts. Request an actual broker quote and check spreads/fees before any action. Reassess if the next two reports do not quantify the cash consequence of migration and agents. This is not suitable for every reader.

What happens next?

Issuer investor calendar listed fiscal-2027 third-quarter results for 3 December 2026; verify that event date again before relying on it. Test actual subscription growth, cash from operations, software margins and commentary about AI products. An announced customer is not a new earned subscription until recognised under accounting rules.

OTR tracking record

Original entry price and date (permanent, frozen field): US$301.53 per share, 13 Nov 2026 16:00 EST, US market closing reference; original source: https://stockanalysis.com/stocks/veev/history/. Latest checked price: same closing price only; no later independent regular-session quote available as of report cutoff. Price change: 0.00% since frozen tracking snapshot only, not an actual investment return. Estimated result after costs: NOT ASSESSABLE; unknown broker spread, commission, custody, FX, distributions and taxes; no costs were incurred by this research. Actually sold? NO, no purchase executed. Forecast status: NOT YET DUE; these are first-publication scenarios. Next review: 2026-12-03. Do not rewrite the frozen original price or forecast when new evidence appears; append a separately dated update.

Dated verification note

Verification, 16 November 2026 (SGT): All eight original URLs reopened. Q1 fiscal-2027 revenue of US$882.9 million and Q2 US$928 million, including US$766.8 million subscription revenue, are reported revenue, not annual recurring revenue or collected cash. March and September deployment counts are issuer claims; selections and available agent products do not establish separate paid agent revenue. The July-period 10-Q describes generally terminable multi-year subscriptions and EU Data Act cancellation rights, so switching costs do not guarantee retention. The frozen US$301.53 is the 13 November 2026, 16:00 EST historical close; US$301.48 at 19:58 EST that date (14 November 08:58 SGT) is a separate after-hours observation, neither an executable entry. A separately checked issuer-issued release dated 12 November confirms planned 3 December results after market close and a 17:00 ET call (4 December 06:00 SGT); this is scheduled, not completed. The direct investor-relations event feed was empty during this check. The original source register below is preserved; the SEC reference date denotes the reporting period, not a verified filing-publication date.

Additional verification source: Veeva scheduled results announcement, 12 November 2026.

Original forecast date and time

2026-11-15T15:58:00+08:00

Forecasts and review dates

6 months

Review date

2027-05-15

Original forecast

Count deployed Vault CRM customers in next issuer update

What to measure

Count deployed Vault CRM customers in next issuer update

What must happen

Count deployed Vault CRM customers in next issuer update

What would challenge the forecast

Customer churn or implementation overruns already evident

Current outcome

Not yet due

1 year

Review date

2027-11-15

Original forecast

Compare new subscriptions and agent product pricing with cash generation

What to measure

Compare new subscriptions and agent product pricing with cash generation

What must happen

Compare new subscriptions and agent product pricing with cash generation

What would challenge the forecast

Subscription growth slows while expenses accelerate

Current outcome

Not yet due

2 years

Review date

2028-11-15

Original forecast

Look for a separately disclosed AI/CRM renewal cohort

What to measure

Look for a separately disclosed AI/CRM renewal cohort

What must happen

Look for a separately disclosed AI/CRM renewal cohort

What would challenge the forecast

Management still does not isolate monetisation

Current outcome

Not yet due

3 years

Review date

2029-11-15

Original forecast

Look for operating cash growth exceeding equity dilution over two fiscal cycles

What to measure

Look for operating cash growth exceeding equity dilution over two fiscal cycles

What must happen

Look for operating cash growth exceeding equity dilution over two fiscal cycles

What would challenge the forecast

Cash growth stalls despite rising reported adjusted metrics

Current outcome

Not yet due

4 years

Review date

2030-11-15

Original forecast

Test sustained customer retention and returns on product investment

What to measure

Test sustained customer retention and returns on product investment

What must happen

Test sustained customer retention and returns on product investment

What would challenge the forecast

Major customers migrate to alternative software

Current outcome

Not yet due

5 years

Review date

2031-11-15

Original forecast

Check five-year subscription mix versus competitive pricing pressure

What to measure

Check five-year subscription mix versus competitive pricing pressure

What must happen

Check five-year subscription mix versus competitive pricing pressure

What would challenge the forecast

Legacy platform disruption or falling renewal rates

Current outcome

Not yet due

Sources

Dated source

  1. Source ID

    VEEV-S1

    What this source supports

    Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Direct page opened. Supports: Subscription and total revenue; primary earnings source.

  2. Source ID

    VEEV-S2

    What this source supports

    Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Web-retrieved/search-indexed. Supports: Quarterly revenue comparison.

  3. Source ID

    VEEV-S3

    What this source supports

    Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Direct page opened. Supports: Customer deployment milestone.

  4. Source ID

    VEEV-S4

    What this source supports

    Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Direct page opened. Supports: 190 customer claims and commitments versus live deployments.

  5. Source ID

    VEEV-S5

    What this source supports

    Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Web-retrieved/search-indexed. Supports: Product availability not proven monetisation.

  6. Source ID

    VEEV-S6

    What this source supports

    Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Web-retrieved/search-indexed. Supports: Selected versus implemented distinction.

  7. Source ID

    VEEV-S8

    What this source supports

    Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Direct page opened. Supports: Reference market close; not executed trade.

Source limits

Original source register

At least eight asset-relevant references, with full URLs. Source check window: 15 November 2026, 15:58 SGT (edition-level clock; exact upstream HTTP completion time per URL not retained). Link status says whether the page was directly opened, or identified in web search and corroborated with the issuer/index. Dates marked unknown are not invented.

1. Fiscal 2027 Q2 results | Veeva | Original: 26 Aug 2026 | US / English.

Direct URL: https://www.veeva.com/resources/veeva-announces-fiscal-2027-second-quarter-results/

Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Direct page opened. Supports: Subscription and total revenue; primary earnings source.

2. Fiscal 2027 Q1 results | Veeva | Original: 3 Jun 2026 | US / English.

Direct URL: https://www.veeva.com/resources/veeva-announces-fiscal-2027-first-quarter-results/

Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Web-retrieved/search-indexed. Supports: Quarterly revenue comparison.

3. 125+ customers live on Vault CRM | Veeva | Original: 3 Mar 2026 | US / English.

Direct URL: https://www.veeva.com/resources/more-than-125-customers-worldwide-live-on-vault-crm-as-veeva-accelerates-the-industrys-agentic-transformation/

Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Direct page opened. Supports: Customer deployment milestone.

4. Vault CRM extends market leadership | Veeva | Original: 23 Sep 2026 | US / English.

Direct URL: https://www.veeva.com/resources/vault-crm-extends-market-leadership-as-another-top-20-biopharma-chooses-veeva/

Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Direct page opened. Supports: 190 customer claims and commitments versus live deployments.

5. Veeva AI agents now available | Veeva | Original: 3 Dec 2025 | US / English.

Direct URL: https://www.veeva.com/resources/veeva-ai-agents-now-available-to-increase-productivity-and-customer-centricity/

Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Web-retrieved/search-indexed. Supports: Product availability not proven monetisation.

6. Regeneron selects Vault CRM | Veeva | Original: 25 Aug 2026 | US / English.

Direct URL: https://www.veeva.com/resources/veeva-vault-crm-selected-by-regeneron/

Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Web-retrieved/search-indexed. Supports: Selected versus implemented distinction.

7. Veeva 10-Q July 2026 | US SEC / Veeva | Original: 31 Jul 2026 period | US / English.

Direct URL: https://www.sec.gov/Archives/edgar/data/1393052/000139305226000036/veev-20260731.htm

Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Web-retrieved/search-indexed. Supports: Financial and operating risks, actual accounts.

8. VEEV dated trading history | Stock Analysis | Original: 13 Nov 2026 quote | US / English.

Direct URL: https://stockanalysis.com/stocks/veev/history/

Checked: 15 November 2026, 15:58 SGT (edition research window; exact per-URL upstream timestamp unavailable). Verification: Direct page opened. Supports: Reference market close; not executed trade.

Back to Signals